Search company, investor...
Search
Encoded Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

encoded.com

Founded Year

2014

Stage

Series E | Alive

Total Raised

$239.12M

About Encoded Therapeutics

Encoded Therapeutics is a biotechnology company that advances precision medicines for a broad range of genetic disorders. Encoded Therapeutics delivers life-changing advances for individuals with genetic disorders not addressable with current approaches.

Encoded Therapeutics Headquarters Location

341 Oyster Point Blvd.

South San Francisco, California, 94080,

United States

650-491-0272

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Encoded Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Encoded Therapeutics in 2 CB Insights research briefs, most recently on Oct 8, 2020.

Expert Collections containing Encoded Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Encoded Therapeutics is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

16,373 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Encoded Therapeutics Patents

Encoded Therapeutics has filed 12 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Transcription factors
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/5/2018

12/31/2019

Transcription factors, Molecular biology, Genetics, Biotechnology, Rare diseases

Grant

Application Date

10/5/2018

Grant Date

12/31/2019

Title

Related Topics

Transcription factors, Molecular biology, Genetics, Biotechnology, Rare diseases

Status

Grant

Latest Encoded Therapeutics News

Encoded Therapeutics Presents Nonclinical Data Showing Genomic Medicine Platform Yields Selective Expression to Optimize Gene Therapy Performance at the American Society for Cell and Gene Therapy 25th Annual Meeting

May 18, 2022

Multiple adaptable DNA sequence-encoded human genetic elements are modality-agnostic and can be combined to customize expression profiles to optimize therapeutic approaches in and beyond the brain May 18, 2022 07:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Encoded Therapeutics announced nonclinical data being presented today at the American Society for Cell and Gene Therapy 25th Annual Meeting showing how its proprietary human genomic regulatory element (RE) engineering platform has been used to develop cell-selective expression vectors for targeted gene therapy. The company efficiently discovered a spectrum of sequence-encoded genetic elements, including enhancers, promoters and UTR elements, that drive selective expression profiles in mice. These REs function within the size constraints and episomal architecture of adeno-associated viruses (AAVs) and are compatible with multiple capsids and gene delivery systems. “By combining human genomic regulatory elements to customize expression profiles and minimize off-target effects, we aim to improve the safety and efficacy of gene therapies for a broad range of monogenic and non-monogenic diseases in the future,” said Encoded CEO Kartik Ramamoorthi, Ph.D. “Our regulatory elements engineering approach increases cell-selective expression, reducing toxicity concerns in tissues like the liver. The data we’re sharing today at ASGCT are exemplary of the Encoded platform’s ability to achieve appropriately targeted transgene expression across many other central nervous system (CNS) cell types, like dorsal root ganglia (DRG) neurons, as well as non-CNS cell types​.” Using Encoded's genomic medicine platform, researchers applied both expression-based functional screening and computational modeling to simultaneously test thousands of genomic elements in vivo. They uncovered sequence elements that selectively decrease liver expression while maintaining CNS expression in mice. Additionally, the research team constructed predictive models to rapidly and iteratively continue to improve the discovery rate and distribution of activity profiles, resulting in further reduction of liver expression in mice, with unchanged expression in the brain. Click here for the abstract of Encoded’s ASGCT presentation, “Optimized Human Regulatory Sequences Achieve Targeted Expression in CNS and Decreased Liver Expression in Mice.” About Encoded Therapeutics Encoded Therapeutics is creating one-time, disease-modifying gene therapies for pediatric central nervous system (CNS) disorders with its cell-selective targeting and regulation platform. The Encoded approach offers unprecedented gene specificity and cell selectivity to unlock novel opportunities by targeting a range of disease mechanisms. Encoded’s technology is compatible with any delivery system to control where and when therapeutic transgenes are expressed, thereby shaping the functionality of target cells and holding broader therapeutic potential beyond CNS disorders. For more information, please visit www.encoded.com , and follow us on LinkedIn , Twitter @EncodedTx and YouTube . Contacts

Encoded Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Encoded Therapeutics Rank

  • When was Encoded Therapeutics founded?

    Encoded Therapeutics was founded in 2014.

  • Where is Encoded Therapeutics's headquarters?

    Encoded Therapeutics's headquarters is located at 341 Oyster Point Blvd., South San Francisco.

  • What is Encoded Therapeutics's latest funding round?

    Encoded Therapeutics's latest funding round is Series E.

  • How much did Encoded Therapeutics raise?

    Encoded Therapeutics raised a total of $239.12M.

  • Who are the investors of Encoded Therapeutics?

    Investors of Encoded Therapeutics include ARCH Venture Partners, Illumina Ventures, RTW Investments, Menlo Ventures, Matrix Capital Management and 15 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.